GTHA – GeneThera, Inc. — Stock Guru Profile GeneThera, Inc. (OTCBB:GTHA)
GeneThera and the Road to Italy/on the Road to Italy
Dr. Tony Milici – Chairman of the Board, President & CEO
GeneThera was able to develop a molecular blood test for Mad Cow Disease here in the United States. However, to complete the clinical trials they were required to regroup and complete their clinical trials in Italy because of the FDA’s ban and one sided cooperation.
Clinical Trials at GeneThera, Inc. started about a year ago with the animals collecting blood samples to set up the molecular tests. This phase of testing is known as the Research and Development stage.
In this first Research and Development stage molecular tests are run on animal blood. GeneThera was able to initiate these tests with blood from several animals that were slaughtered in the United States. For this portion of the study samples obtained from animals with CWD (chronic wasting disease) which is in the same family of mad cow disease but infects mainly elk and deer. GeneThera was able to obtain 600 samples which came from mixed animals from different herds infected with Mad Cow Disease. These animals were from South Dakota, Minnesota, and Canada from herds that had Mad Cow Disease infections. GeneThera was able to start testing animals with their molecular assay.
The second stage is known as the validation stage. In this stage a sample collection from different locations is made and there is a comparison made with the testing being done by the USDA. Enter – a serious problem. The USDA is glad to take Dr. Milici’s research but refuses to share the results of their research with him.
Dr. Milici notes that in Italy the validation and clinical trial will be conducted in accord with scientific principles. Each entity will run their own test and afterwards will compare their individual results. GeneThera will take 10,000 samples, run their molecular blood test while at the same time the Italian Institute will continue to run their same tests. GeneThera will then determine how their test stacks up. The specimens will continue to be available to reconcile any differences.
About GeneThera, Inc. GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company’s proprietary diagnostic solution is based on a genetic expression assay, GEA(TM), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Mad Cow disease, Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7 and Johnne’s Disease, diseases affecting cattle worldwide.
About IZSLER Istituto Zooprofilattico Sperimentale della Lombardia e dell’Emilia Romagna (IZSLER),(www.bs.izs.it), offers a broad range of services in the Public Veterinary sectors in particular, Food Safety to the Veterinary Services, Breeders and Consumers. Its functions today can be described as those of a Technical-Scientific Body providing services as required of it by national and regional law. At the present, IZSLER employs over 600 persons, 90 of them are graduated scientists (veterinarians, biologists and chemists). On a regional basis (Lombardia and Emilia Romagna), IZSLER performs diagnosis for a variety of viral infectious diseases of ruminants, pigs, horses, poultry and other species of economic interest (rabbits, fishes, bees….), and microbiological and chemical analysis on foodstuffs of animal origin destined for human consumption and on food resources for animals.
“Safe Harbor” Statement: Certain statements in this release are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company’s ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.
Forward Loooking Statement: A number of statements contained in this report are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com .
Disclosure: Pentony Enterprises LLC: was compensated 500,000 free trading shares from a non-controlling third party for profile coverage. Pentony Enterprises is not a registered investment advisers or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.
